A detailed history of Parallel Advisors, LLC transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Parallel Advisors, LLC holds 126 shares of DVAX stock, worth $1,616. This represents 0.0% of its overall portfolio holdings.

Number of Shares
126
Previous 37 240.54%
Holding current value
$1,616
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$10.05 - $11.61 $894 - $1,033
89 Added 240.54%
126 $1,000
Q2 2024

Aug 08, 2024

BUY
$10.73 - $12.58 $397 - $465
37 New
37 $0
Q3 2023

May 20, 2024

SELL
$12.64 - $14.99 $6,320 - $7,495
-500 Reduced 28.57%
1,250 $18,000
Q3 2023

Nov 13, 2023

SELL
$12.64 - $14.99 $6,320 - $7,495
-500 Reduced 28.57%
1,250 $18,000
Q2 2023

May 20, 2024

BUY
$9.85 - $13.17 $2,669 - $3,569
271 Added 18.32%
1,750 $22,000
Q2 2023

Aug 04, 2023

BUY
$9.85 - $13.17 $2,669 - $3,569
271 Added 18.32%
1,750 $22,000
Q1 2023

May 20, 2024

BUY
$9.44 - $11.88 $13,961 - $17,570
1,479 New
1,479 $14,000
Q1 2023

Apr 25, 2023

BUY
$9.44 - $11.88 $2,161 - $2,720
229 Added 18.32%
1,479 $14,000
Q1 2022

Apr 28, 2022

SELL
$9.75 - $14.44 $165 - $245
-17 Reduced 1.34%
1,250 $14,000
Q4 2021

Jan 20, 2022

BUY
$13.17 - $20.94 $223 - $355
17 Added 1.36%
1,267 $18,000
Q4 2020

Feb 02, 2021

SELL
$3.73 - $5.6 $1,119 - $1,680
-300 Reduced 19.35%
1,250 $6,000
Q4 2019

Jan 30, 2020

BUY
$3.46 - $6.93 $1,038 - $2,079
300 Added 24.0%
1,550 $9,000
Q3 2017

Nov 15, 2017

BUY
$15.2 - $21.5 $19,000 - $26,875
1,250
1,250 $23,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.62B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.